Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3437095 | 1.00 | TK1 (0.65) | TK1POLB | |
| SCHEMBL538835 | 1.00 | TK1 (0.65) | TK1POLB | |
| SCHEMBL25521507 | 1.00 | TK1 (0.65) | TK1POLB | |
| SCHEMBL538834 | 1.00 | TK1 (0.65) | TK1POLB | |
| SCHEMBL655193 | 0.92 | TK1 (0.67) | TK1POLB | |
| SCHEMBL19224119 | 0.89 | TK1 (0.69) | TK1POLB | |
| SCHEMBL14063727 | 0.89 | TK1 (0.69) | TK1POLB | |
| Doxribtimine SCHEMBL10382149 | 0.89 | TK1 (0.73) | TK1 | |
| SCHEMBL12352406 | 0.89 | TK1 (0.69) | TK1POLB | |
| Doxribtimine SCHEMBL21078835 | 0.89 | TK1 (0.73) | TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807653-B2 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2010-10-05 | — | — | US | disclosed |
| US-7598230-B2 | For the treatment of viral infections, microbial infections, and proliferative disorders; contain di- or triphosphate moeity mimetics, such as those containing boron anions | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2009-10-06 | — | — | US | disclosed |
| US-20070265224-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-15 | — | — | US | disclosed |
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-08 | — | — | US | disclosed |
| US-7285658-B2 | Nucleotide mimics and their prodrugs | BIOTA, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | TK1 62/4885POLB 623/4885 |
| US-20070265224-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | TK1 62/4885POLB 623/4885 |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | TK1 62/4885POLB 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.